Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

0.4354
-0.0300-6.45%
Post-market: 0.4343-0.0011-0.25%16:59 EDT
Volume:8.16M
Turnover:3.37M
Market Cap:40.00M
PE:-0.90
High:0.4748
Open:0.4700
Low:0.3969
Close:0.4654
52wk High:3.62
52wk Low:0.3969
Shares:91.88M
Float Shares:63.73M
Volume Ratio:3.12
T/O Rate:12.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4828
EPS(LYR):-0.3800
ROE:-76.14%
ROA:-45.70%
PB:1.05
PE(LYR):-1.15

Loading ...

Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial

TIPRANKS
·
Jun 15

Context Therapeutics reports 29% response rate in Phase 1 trial of CTIM-76 for platinum-resistant ovarian cancer

Reuters
·
Jun 15

Context Therapeutics Announces Positive Interim Efficacy and Safety Results From Ongoing Phase 1 Clinical Trial for Ctim-76

THOMSON REUTERS
·
Jun 15

Context Therapeutics - Ctim-76 Granted FDA Fast Track Designation in Proc

THOMSON REUTERS
·
Jun 15

Context Therapeutics - Reports 29% Confirmed Overall Response Rate in Proc Patients With Median 7 Prior Therapies

THOMSON REUTERS
·
Jun 15

Context Therapeutics grants new hire stock options for 146,000 shares at USD 1.71 each

Reuters
·
Jun 10

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 10

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 10

Context Therapeutics grants new hire stock options for 146,000 shares at USD 2.63 each

Reuters
·
May 27

Context Therapeutics Decline Means Insider Profits Down To US$237k

Simply Wall St.
·
May 19

Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)

TIPRANKS
·
May 19

Context Therapeutics Secures Full Rights to Antibody Assets

TIPRANKS
·
May 18

Context Therapeutics enters license agreement amendment with BioAtla

TIPRANKS
·
May 18

Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties

Reuters
·
May 18

Context Therapeutics Enters Into License Agreement Amendment With Bioatla for Ct-202

THOMSON REUTERS
·
May 18

Context Therapeutics - Announces Buyout of Ct-202 Future Milestones and Royalties

THOMSON REUTERS
·
May 18

Context Therapeutics: Amendment Removes All Future Milestone and Royalty Obligations Owed by Company for Ct-202

THOMSON REUTERS
·
May 18

Context Therapeutics - to Pay $4.5 Mln Upfront and $2.0 Mln by Aug 1, 2026 for Ct-202 License

THOMSON REUTERS
·
May 18

Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)

TIPRANKS
·
May 10

Context Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08